Clinical Trials Updates and Outcomes of Stem Cells Over the Globe- 2024
Stem cell treatments and tests have been happening for more than 60 years. But we’re still figuring out how well stem cell therapy works compared to regular medicine. In the beginning, scientists mainly checked if stem cell treatments worked well and were safe in trials. When we try a new treatment, the most important things we worry about are whether it’s safe for a long time and if it always works the same for everyone. Many scientific journals talk about clinical trials. These trials show good results from tests done in different countries.
Below we mentioned several sources in which doctors are testing stem cells in people’s bodies to see if it can help them get better.
Open Stem Cell Trials: Enrolling New Patients Right Now
- Mesenchymal Stem Cells Combined With Cord Blood for Treatment of Graft Failure – Phase 2 –
- ALS Clinical Trials – US and International – ongoing and updated regularly
- Clinical study iPS cell therapy for eye disease – (Japan)
- Fractionated Stem Cell Infusions in Myeloma Patients Undergoing Autologous Stem Cell Transplant
- Treatment of Knee Osteoarthritis With Allogenic Mesenchymal Stem Cells
- In Vitro Expanded Allogeneic Epstein-Barr Virus Specific Cytotoxic T-Lymphocytes (EBV-CTLs) Genetically Targeted to the B-Cell Specific Antigen CD19 Positive Residual Or Relapsed Acute Lymphoblastic Leukemia After Allogeneic Hematopoietic Progenitor Cell Transplantation
Results of Closed or Completed Stem Cell Trials (mostly conducted in the United States unless specified)
- Autologous stem cell transplantation in adults with acute lymphoblastic leukemia
- ALS and MND Stem Cell Trials at Emory University
- Parametric vs nonparametric statistics
- Clinical applications of mesenchymal stem cells for movement disorders
- In vitro differentiation of human placenta-derived multipotent cells into hepatocyte-like cells.– Cells taken from a human placenta at full term, called placenta-derived multipotent cells (PDMCs), can develop into different types of cells, such as fat cells and bone cells. Placenta cells are good for cell-based therapy because they come from a young source and have a low infection rate compared to other adult stem cells.
- Comparison of human placenta- and bone marrow-derived multipotent mesenchymal stem cells. Bone marrow is usually where we get human multipotent mesenchymal stem cells (MSCs) from, but the placenta seems to be an easier and more available source. This study compared human placenta-derived MSC (hpMSC) and human bone marrow (hbmMSC). It looked at their cell characteristics, the best conditions for their growth, and their safety in living organisms to see if hpMSC could be used for clinical trials. Stem cells were taken from human placenta (hpMSC) and human bone marrow (hbmMSC). These cells were then grown outside the body using materials that meet high safety and quality standards.
- Australian Clinical Trials – Therapy for Peripheral Vascular Disease– A trial in Australia is testing a new treatment for severe peripheral arterial disease. The study will use patients’ own stem cells from their blood, delivered directly into their arteries. The trial is double-blind and randomized, meaning neither the patients nor the researchers know who is receiving the actual treatment. The goal is to see if this method is safe and practical. The trial is happening at Alfred Hospital in Melbourne, and they plan to sign up 20 people. Scientists put subjects into two groups by chance. One group will get a shot of special stem cells through their limb artery (that’s the experimental group), and t he other group will get a fake shot (that’s the control group). They will monitor the participants closely for any problems and check if their health gets better or worse.
- The Transendocardial Autologous Cells (hMSC or hBMC) in Ischemic Heart Failure Trial (TAC-HFT)– Transplanting young cells into a damaged heart muscle, called cellular cardiomyoplasty, is a new treatment method. It aims to replace or fix dead, scarred, or weak heart tissue. Ideally, graft cells should be easy to get, simple to grow in large numbers, and able to survive in the host’s heart tissue, which can be a tough place with poor blood supply and immune system rejection.
